Biotech Breakthrough Could Save Millions Of Lives And Billions Of Dollars (SPONSORED POST)

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Someone dies of a stroke every 4 minutes in the United States. Globally, 15 million people suffer a stroke every year. It’s debilitating physically and financially—but one little-known company has developed a medical device that hopes to challenge that deadly statistic.

It’s been quietly developing this new technology for 10 years. Now it’s released updated preliminary clinical trial results, and signed a manufacturing deal which could make a significant impact in the medical device industry.

After a decade of painstaking development, we’re now nearing the end of the long road to validation, and for investors who understand this industry, this could be the critical juncture.

The little-known company is CVR Medical (TSX:CVM.V; OTC:CRRVF), and its potentially life-saving device is the Carotid Stenotic Scan (CSS)--a technology designed to detect stenosis within arteries, or Ischemia, which is the leading indicator of strokes.

Of the 15 million people who suffer stroke every year, some 6 million are killed, while 5 million are rendered permanently disabled, according to the World Heart Foundation.

But there has been no cost-effective way to screen for Ischemia.

So, when a biotech company offers a potential solution to help prevent the second-leading cause of death in the world--and then releases positive preliminary clinical trial results, investors listen.

Now it’s hoping to charge out of the gate and take the market by storm once it manages to gain FDA market clearance.

In the meantime, the catalysts are really lining up:

On 7 September, CVR released updated results from its preliminary clinical trial that showed forward progress for the medical device, which we’ve been watching closely for some time. You can view the results from Thomas Jefferson University HERE.

And a few weeks prior, they announced another landmark achievement when they signed a letter of intent to manufacture the CSS. The deal gives CVR state-of-the-art manufacturing capabilities with Canon Virginia, Inc (CVI). This would give CVR immediate scalability, and also adds to its credibility: It’s not the first manufacturing deal the company has sealed.

Our researchers are keeping a close eye on CVR Medical Corp. because we think this is the turning point. Here’s why:

  • It’s had two fresh catalysts in three weeks in an industry that is all about validation
  • It’s developing a device that meets critical demand in terms of helping to prevent one of the most debilitating and deadly diseases of our time
  • It’s developing a medical device that actually makes sense to the market
  • It’s been doing it quietly, without blockbuster hype, and instead painstakingly going for real validation, making it the real deal.

Here are 5 reasons to keep a close eye on CVR Medical (TSX:CVM.V; OTC:CRRVF) in the coming weeks and months:

#1 Catalysts are Lining Up, and News Flow is Gaining Momentum

First, one way to look at the CSS is to think about what 3D seismic imagery did for super quick discoveries in the oil and gas industry. This is exactly what CVR’s sensory system could do for the medical industry in terms of detecting critical stroke symptoms.

This is how it works:

CVR’s Carotid Stenotic Scan (CSS) is a tool to detect blockage within the Carotid Arteries, potentially offering patients and caregivers a device for early detection in a quick and repeatable manner.

The CSS makes a connection between fluid flow and low frequency sound waves to detect arterial disease or blockage. Blood flowing through the carotid arteries produces wave patterns which are shaped and altered by the presence of irregularities on the inner artery walls.

1 2 3 4
View single page >> |

Disclaimer: PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities., Advanced Media Solutions Ltd, and their owners, ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
BreakingBad News 2 years ago Member's comment

Looks good.

Micro Blogger 2 years ago Member's comment

Liked this, thanks. Bullish on $CRRVF.

Tracey Nichols 2 years ago Member's comment


Alexis Renault 2 years ago Member's comment

Is having only $2 million in the bank for such a large company considered a good thing? Between salaries and continued R&D expenditures, I would think that's rather low. Can anyone else weigh in to let me know? Otherwise I find $CRRVF to be an intriguing prospect.

Henry L. Morgan 2 years ago Member's comment

This sounds very promising, but I'd be interested in seeing some more hard facts. I read the link to the actual clinical trial results but it didn't give much information other than saying that most patients responded favorably. Which obviously is a good sign but I'd like to dig deeper before I invest.

Old Time Investor 2 years ago Member's comment

I agree, but that alone is a good sign. Looking forward to more on $CRRVF,

Ayelet Wolf 2 years ago Member's comment

Sounds good. What are the risks/downsides to investing in $CRRVF though?

Terrence Howard 2 years ago Member's comment

I've always appreciated being able to make money on an investment, while knowing that investment can help people at the same time!

Susan Miller 2 years ago Member's comment

Investing aside, this is extremely promising. Anything that will help live longer is good news. I just had a friend that suffered a stroke. Here's hoping for further positive results! $CRRVF

Harry Goldstein 2 years ago Member's comment

From your mouth to God's ear.

Dan Jackson 2 years ago Member's comment

I always take sponsored post with a grain of salt, but this is definitely worth a closer look! Any independent analysis available on this stock?

Alexa Graham 2 years ago Member's comment

I'll echo that comment.

Alpha Stockman 2 years ago Member's comment

This sums up everything you need to know: "So, when a biotech company offers a potential solution to help prevent the second-leading cause of death in the world--and then releases positive preliminary clinical trial results, investors listen."

I'm listening! Eager to learn more about #CVRmedical $CRRVF